Hi Analyst007, it is interesting the details of the 60 patient...

Hi Analyst007, it is interesting the details of the 60 patient trial you have dug out. It looks as if it is a single site trial at the EYE institute in Melbourne. It is double blinded so will have credible results and I vaguely recall Tom talking about this trial discussed with the fda as a precursor trial before any large trial implementation in the US. It is great news that results should come soon after end of July 2023. It may be wishful thinking but I think I remember Tom saying a successful ourcome of this 1 year trial would enable them to present this data to fda and then get the go ahead to include us sites in 2 the multiyear, mulicountry trials outlined by Robyn last week.